文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICU.

作者信息

Tandjaoui-Lambiotte Yacine, Akrour Yanis, Gibelin Aude, Gonzalez Frederic, Stoclin Annabelle, Moreau Anne-Sophie, Jaubert Paul, Oppenheimer Anne, Duchemann Boris, Gaudry Stéphane

机构信息

Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, APHP, Bobigny, France; Hypoxia & Lung, INSERM, U1272, Bobigny, France.

Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, APHP, Bobigny, France.

出版信息

Chest. 2022 Jan;161(1):284-287. doi: 10.1016/j.chest.2021.06.079. Epub 2021 Jul 21.

DOI:10.1016/j.chest.2021.06.079
PMID:34302842
Abstract
摘要

相似文献

[1]
Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICU.

Chest. 2022-1

[2]
Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma.

J Thorac Oncol. 2018-11

[3]
Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival.

Future Oncol. 2020-12

[4]
Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.

Lung Cancer. 2018-4

[5]
Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.

Cancer Med. 2021-3

[6]
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.

BMC Cancer. 2021-11-19

[7]
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.

Lung Cancer. 2020-3

[8]
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.

N Engl J Med. 2019-11-21

[9]
Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.

Clin Ther. 2019-1-11

[10]
Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).

Int J Oncol. 2021-2

引用本文的文献

[1]
Scalable Production and In Vitro Efficacy of Inhaled Erlotinib Nanoemulsion for Enhanced Efficacy in Non-Small Cell Lung Cancer (NSCLC).

Pharmaceutics. 2023-3-20

[2]
Prognostic factors for advanced lung cancer patients with do-not-intubate order in intensive care unit: a retrospective study.

BMC Pulm Med. 2022-6-24

[3]
Patterns of ICU admissions and outcomes in patients with solid malignancies over the revolution of cancer treatment.

Ann Intensive Care. 2021-12-24

[4]
Factors associated with impaired quality of life three months after being diagnosed with COVID-19.

Qual Life Res. 2022-5

[5]
[Morphological and functional sequelae after COVID-19 pneumonia].

Radiologe. 2021-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索